Stroke Drug Development Targeting Gut Microbiota

Studies have shown that gut microbiota plays an important role in the development and treatment of stroke. Stroke alters the composition of the gut microbiota, and gut microbiota likewise modulates the process of stroke development through multiple pathways, such as bacterial composition, microbiota metabolites, and immunity. Therefore, scientists at Ace Therapeutics has established a completed and proven service process to facilitate the development of stroke drugs targeting the gut microbiota.

Development of Fecal Microbiota Transplant for Stroke

The aim of fecal microbiota transplant (FMT) aims to repair the gut microbiota by transplanting healthy donor feces, which modifies the integrated gut microbiota and creates a stable state. Studies have shown that transplantation of short chain fatty acids -rich fecal microbes is indeed an effective pathway for the treatment of stroke. Therefore, Ace Therapeutics provides appropriate services to facilitate the development of stroke drugs.

• We have established a complete process and methodology to prepare and store frozen feces to ensure the efficacy of feces from healthy donors.
• By combining 16S/18S/ITS amplicon sequencing, metagenomic sequencing, and next-generation sequencing with bioinformatics analysis, we screen for other gut microbes and their metabolites with protective effects against brain diseases to enrich the variety of selectable fecal microbes.
• Common routes of fecal microbiota transplantation include capsules, nasal-intestinal delivery methods, and fecal transplant enemas. We provide different experimental animals to establish stroke models to validate and optimize the fecal transplantation route.

Development of Bacterial Formulation for Stroke

Many bacteria have been used to develop drugs to treat disease, but screening hundreds of gut microbiota for bacteria that can be used to develop stroke drugs is not an easy task. Ace Therapeutics provides advanced and sophisticated services to accelerate the development of bacterial drugs for stroke treatment.

• We have built a bacterial screening platform based on artificial intelligence computing technology that can accurately screen for bacterial populations that are closely related to stroke.
• We have built proven techniques to optimize bacterial formulations in terms of numbers and ratios of bacteria.
• We have constructed various in vitro and in vivo models to validate the feasibility of bacterial formulations and their therapeutic efficacy in stroke.

Development of Small Molecule Regulators for Stroke

Small molecule regulators include bacterial metabolites, compounds, and peptides. Short-chain fatty acids derived from the gut microbiota can promote recovery after stroke, while many small molecule compounds and peptides can also treat stroke by modulating the gut microbiota. Therefore, Ace Therapeutics offers a well-established service to further explore the potential therapeutic effects of small molecule modulators on stroke.

• We establish a gut microbiota targeted metabolomics analysis platform to provide high-throughput absolute quantitative assays of known metabolites.
• we offer a gut microbiota untargeted metabolomics platform to analyze metabolic profiles, dynamic changes in metabolic levels, and screening for differential metabolites.
• Based on our ultra-large compound library, natural product library, and fragment library, we provide an in vitro platform that enables rapid screening, allowing rapid access to a large number of modulators of intestinal function, which can then be further validated by stroke models.

If you would like to learn more about our services, please feel free to contact us.

1. Pluta, R., et al., The role of gut microbiota in an ischemic stroke. Int J Mol Sci, 2021. 22(2).
2. Yamashiro, K., et al., Role of the gut microbiota in stroke pathogenesis and potential therapeutic implications. Ann Nutr Metab, 2021. 77 Suppl 2(Suppl 2): p. 36-44.